Watch a highlight reel of breast cancer data from ASCO 2026 that experts anticipate will have the biggest impact on the field.
Commentary|Articles|December 18, 2025
Experts Highlight SABCS 2025 Data With Potential to Shift Breast Cancer Practice
Author(s)Jax DiEugenio
Fact checked by: Ashling Wahner
Breast oncology experts discuss SABCS 2025 data from HER2CLIMB-05 and lidERA that may influence maintenance therapy and adjuvant endocrine care.
Advertisement
Advertisement
The
Related to this article
A post-hoc analysis of LITESPARK-005 found that higher baseline and improved on-treatment QOL scores tracked with lower risk of disease progression and death.
Dato-DXd was approved in the European Union as monotherapy for patients with first-line metastatic TNBC who are not candidates for immunotherapy.
Experts go step by step in laying out their thought processes and treatment selections for difficult-to-treat lung cancer cases.
Two decades of biomarker-driven progress have reshaped lung cancer management, but late diagnosis, unequal treatment access, and underfunding remain
Phase 3 data support EGFR and ALK inhibitors as adjuvant standards of care in resectable NSCLC.
Max Diehn, MD, PhD, breaks down how ctDNA testing for MRD is reshaping prognostic discussions in NSCLC.
Five-year outcomes from neoadjuvant, adjuvant, and perioperative immunotherapy trials in resectable NSCLC clarify which patients benefit most.
Advertisement
Advertisement